Peptide & Hormone Therapy for Men & Women Over 40: Telehealth Platform Launched

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Get Pep'd has announced the launch of its telehealth platform, connecting men and women over 40 across the United States with licensed providers for peptide and hormone therapy consultations.

-- Get Pep'd has launched its telehealth platform, connecting adults over 40 across the United States with licensed providers for testosterone therapy, menopause-related hormone care, and peptide consultations.

More information is available at https://getpepd.com/

The platform rollout comes at a time when hormone-related changes are becoming a bigger focus in preventive and age-management care. According to the National Health Service (NHS), men’s testosterone levels typically decline by about 1% per year from around age 30, while women often experience a more significant hormonal shift during menopause, most commonly between ages 45 and 55. Get Pep’d was built to support adults through these changes by connecting them with licensed providers who can review symptoms, evaluate treatment options, and guide hormone and peptide therapy through a telehealth-based care model.

Get Pep'd's hormone therapy track includes testosterone therapy for men and estrogen and progesterone therapy for women navigating menopause, with treatment plans based on bloodwork rather than a fixed protocol. The platform also connects patients with providers for peptide consultations prescribed only when a licensed provider determines a patient's case warrants it.

The platform connects patients with an independent, nationwide network of licensed clinicians rather than practicing medicine directly. Patients begin with a complimentary 2-minute assessment, followed by provider review and, where appropriate, at-home or local lab testing. The lab-first approach is intended to give providers a clearer clinical picture before any plan is built, rather than relying solely on a patient's self-reported symptoms. Treatment is only prescribed if a licensed provider determines it is clinically appropriate, and patients are not charged unless a plan is approved.

Get Pep'd operates in all 50 states, with providers licensed in each patient's state of residence. Clinical services are provided exclusively by these independent providers, and Get Pep'd does not diagnose or prescribe directly. Ongoing communication between patients and their clinical team is available throughout the course of treatment, allowing adjustments to be made as new lab results come in.

Adults interested in a hormone or peptide assessment can find more information at https://getpepd.com/

Contact Info:
Name: Bryan Calcott
Email: Send Email
Organization: Get Pep'd
Address: 1001 S Main St #12636, Kalispell, Montana 59901, United States
Phone: +1-415-619-7661
Website: https://getpepd.com

Source: PressCable

Release ID: 89195885

In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  227.01
-7.26 (-3.10%)
AAPL  275.15
-17.93 (-6.12%)
AMD  532.57
+12.83 (2.47%)
BAC  58.19
+0.46 (0.80%)
GOOG  342.19
-2.85 (-0.83%)
META  542.87
-14.80 (-2.65%)
MSFT  352.83
-12.63 (-3.46%)
NVDA  195.74
-3.26 (-1.64%)
ORCL  152.46
-5.07 (-3.22%)
TSLA  375.12
-0.41 (-0.11%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.